Figure 2.
Treatment effect of dapagliflozin by risk category predicted by the biomarker-based risk score. ARR was calculated by subtracting the Kaplan-Meier event rates for HHF at 4 years in patients treated with dapagliflozin from the Kaplan-Meier event rates for HHF at 4 years in patients treated with placebo across each risk score category. There was a significant gradient of increasing ARR with increasing risk category.